Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - Pharmaceutical Development - July 28, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/28/17 - "Contrast Agents for Magnetic Resonance Imaging" in Patent Application Approval Process (USPTO 20170189559)
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventor Lascola, Christopher David, filed on March 17, 2017, was made available online on July 13, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. In the U.S., all nine FDA- approved MRI contrast agents are Gd-
7/28/17 - Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug...
By a News Reporter-Staff News Editor at Drug Week Although 10 new opioid products with abuse-deterrent formulations have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the Tufts Center for the Study of Drug Deve
7/28/17 - Agile Therapeutics Reports Second Quarter 2017 Financial Results
Agile Therapeutics, Inc., a women's healthcare company today reported financial results for the three and six months ended June 30, 2017, and provided a corporate update for the second quarter 2017.. On July 27, 2017, the Company announced that the FDA had acknowledged the resubmitted NDA for Twirla as a complete response to the CRL, and provided
7/28/17 - AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot
Agile Therapeutics Inc.' s New Drug Application for Twirla, an investigational low-dose combined hormonal contraceptive patch, has been accepted for review by the FDA- with a decision date set for December 26, 2017. Twirla was turned down by the FDA in 2013. Amgen's supplemental Biologics License Application for Repatha to include data on reducing
7/28/17 - Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR NECTAR (barium sulfate) Oral Suspension
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced the U.S. Food and Drug Administration approved VARIBAR NECTAR oral suspension for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and p
7/28/17 - Clinical laboratory test Market which is probable to reach USD 324.5 billion from USD 206.7 billion till 2022
Clinical Laboratory Test Market Information, by laboratory type, by laboratory test Forecast Till 2022. It has been noted that global clinical laboratory test market is growing at steady pace and is expected to grow at the CAGR of 6.5%. The Centres for Disease Control and Prevention reported that in 2012 alone, US reported 9,945 cases of tuberculos
7/28/17 - Corporate News Blog - Sensus Healthcare Announces Achievement of Approval from China's FDA for SRT-100, the Non-Invasive Superficial Radiation Therapy
LONDON, UK/ ACCESSWIRE/ July 28, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sensus Healthcare, Inc., following which we have published a free report that can be viewed by signing up at Sensus operates in China through its partner, Chindex Medical Limited, a
7/28/17 - Credence Research: Recent Release : Global Biotechnology in India Market Forecasts, Size, Share, Regional Outlook 2017 - Acute Market Reports
This market insight report on Biotechnology in India covers products, technologies and services used in the Indian Biotechnology Industry. The report studies the Bio Pharma, Herbal Drugs, Bioservices and Bioindustrial markets in detail. Major Biopharmaceutical, Bio Fuels, Bioinformatics companies and Contract Research Organizations serving the...
7/28/17 - Dr Reddy`s out licenses phase-3 clinical trial drug to CHD Biosciences [Sudan Tribune]
Dr Reddy`s Laboratories Limited and CHD Bioscience Inc, a privately-held biopharmaceutical company, announced on Thursday, a global licensing agreement for the clinical development and commercialisation of Dr Reddy`s phase III clinical trial candidate, DFA-02. Under the terms of the agreement, Dr Reddy`s would receive equity in Colorado- based CHD
7/28/17 - Findings from University of Connecticut Provides New Data about Pharmaceutical Research (In vitro release testing method development for ophthalmic...
Findings from University of Connecticut Provides New Data about Pharmaceutical Research. By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies- Pharmaceutical Research. The news reporters obtained a quote from the research from the University of Connecticut, "Three different in vitro release tes
7/28/17 - FTC Testifies Before House Judiciary Committee's Subcommittee on Regulatory Reform, Commercial and Antitrust Law About Antitrust Concerns and the FDA Approval Process
The Federal Trade Commission issued the following news release:. In testimony presented to the U.S. House of Representatives' Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to stop anticompetitive conduct in the pharmaceutical industry. Testifying on behalf of
7/28/17 - Infusion Systems Market is expected to be worth $44.33 billion in 2025 with a CAGR of 4.9%
*3 M,* B. BRAUN MELSUNGEN AG,* Baxter,* Becton,* Dickinson and Company,* Fresenius Kabi AG,* ICU Medical, Inc,* Smiths Medical,* Terumo Medical Corporation. *The infusion system global market is expected to reach $44.33 billion by 2025.. *North America holds the largest market share of Infusion System market and is anticipated to reach $15.79 billi
7/28/17 - iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region
iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region. Gosselies, Belgium- July 28, 2017- iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it has been granted EUR 7.5 million in non-dilutive funding* to support the clinical development of its lead anti-cance
7/28/17 - Jamaican scientist`s marijuana-based anti-cancer drug is now FDA approved [Tehran Times (Iran)]
The US Food and Drug Administration recently granted orphan drug approval for Chrysoeriol, a cannabis-based drug used to treat acute myeloid leukaemia, which was developed by Jamaican scientist Dr Henry Lowe. After presenting his research findings at the 2017 Global Health Catalyst Summit at Harvard Medical School in April 2017, Lowe made the annou
7/28/17 - McDonald's cleared after viral video
By Hu Min| 00:01 UTC +8 July 28, 2017| Print Edition. At a McDonald's outlet on Hechuan Road in Minhang District yesterday, officials with the Shanghai Food and Drug Administration checked the license, food materials, operation procedures and hygiene. In a statement, McDonald's China assured customers that its ice cream machines are clean and safe.
7/28/17 - New Carcinomas Findings from M.D. Anderson Cancer Center Outlined (Integrating cytokines and angiogenic factors and tumour bulk with selected...
By a News Reporter-Staff News Editor at Angiogenesis Weekly Fresh data on Oncology- Carcinomas are presented in a new report. Our news journalists obtained a quote from the research from M.D. Anderson Cancer Center, "Seven preselected plasma CAFs were measured using multiplex ELISA in plasma collected pretreatment from 343 mRCC patients participa
7/28/17 - Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
Tiziana Life Sciences plc, the clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, announces publication of a research article in a prestigious journal, Clinical Immunology, entitled: Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in huma
7/28/17 - Rep. Goodlatte Issues Statement at Hearing on 'Antitrust Concerns and the FDA Approval Process'
Bob Goodlatte, R- Va., chairman of the House Judiciary Committee, issued the following statement:. The antitrust laws established in this country serve a valuable role in promoting competition, and the Judiciary Committee routinely exercises its oversight authority to ensure that these laws are applied in a manner that is transparent, fair, predict
7/28/17 - Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients [Syrian Arab News Agency]
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for its Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 as a treatment for severe
7/28/17 - Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger
Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. announced that at separate special stockholder meetings today the stockholders of both companies approved proposals recommended by the Jaguar and Napo boards regarding the merger of Jaguar and Napo. The merger transaction remains on track to become effective on Monday, July 31, 2017, at whic
7/28/17 - Studies from University Hospital Have Provided New Data on Critical Care Medicine (Can proportional ventilation modes facilitate exercise in...
By a News Reporter-Staff News Editor at Health& Medicine Week New research on Health and Medicine- Critical Care Medicine is the subject of a report. According to news reporting originating from Iraklion, Greece, by NewsRx correspondents, research stated, "Early exercise of critically ill patients may have beneficial effects on muscle strength, m
7/28/17 - Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival benefit with Tagrisso compared to current 1st- line standard-of-care treatment in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor...
7/28/17 - Teva Announces Launch of Generic Epiduo in the United States
Teva Pharmaceutical Industries Ltd., today announced the launch of generic Epiduo 1 gel, 0.1%/ 2.5% in the U.S.. With close to 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U
7/28/17 - The FDA has Accepted an Orphan Designation Request for use of Truveta Administered Intranasally Submitted by Axium Pharmaceuticals Inc.
By a News Reporter-Staff News Editor at Drug Week Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug delivery innovations for developing improved novel formulations and alternative dosage forms of existing biologically active molecule. The FDA has accepted an orphan designation request for the intranasal lorazepam,...
7/28/17 - TROVAGENE, INC. FILES (8-K) Disclosing Other Events
On July 27, 2017, Trovagene, Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application for PCM-075, a Polo-like Kinase 1 inhibitor, and has provided authorization to proceed with the treatment of patients with AML.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement